Results 221 to 230 of about 2,666,341 (347)
The plasma proteome and breast cancer risk. [PDF]
Wu HC +6 more
europepmc +1 more source
FIFTEEN-YEAR TO FORTY-YEAR SURVIVAL RATES FOLLOWING RADICAL MASTECTOMY FOR CANCER OF THE BREAST*
Stuart W. Harrington
openalex +2 more sources
Long‐Term Evaluation of Givinostat in Duchenne Muscular Dystrophy, and Natural History Comparisons
ABSTRACT Objectives This ongoing, open‐label extension study is evaluating the long‐term safety, tolerability, and efficacy of givinostat, a Class I and II histone deacetylase inhibitor, in patients with Duchenne muscular dystrophy (DMD). Methods The recruited patients completed one of two prior clinical studies (one Phase 2 and one Phase 3 [EPIDYS ...
Craig M. McDonald +74 more
wiley +1 more source
Structural Determinants of Racial Disparities in Breast Cancer Survival in Alabama. [PDF]
Fowler ME +5 more
europepmc +1 more source
ABSTRACT Objective Recurrent high‐grade gliomas have a poor prognosis and limited therapeutic options. This study aimed to evaluate the safety and efficacy of SYHA1813, a dual inhibitor of VEGFR and CSF1R, in patients with recurrent high‐grade gliomas.
Zhuang Kang +16 more
wiley +1 more source
Research advances of lactylation modification in breast cancer. [PDF]
Shen P, Yang M.
europepmc +1 more source
RESULTS OF OPERATIVE TREATMENT OF CANCER OF THE BREAST
Frank S. Mathews
openalex +2 more sources
Durability of Response to B‐Cell Maturation Antigen‐Directed mRNA Cell Therapy in Myasthenia Gravis
ABSTRACT Objective We report the 12‐month follow‐up outcomes from a Phase 2 clinical trial (NCT04146051) evaluating Descartes‐08, a BCMA‐directed RNA chimeric antigen receptor T‐cell (rCAR‐T) therapy for refractory generalized myasthenia gravis (MG).
Nizar Chahin +10 more
wiley +1 more source
Dear Breast Cancer Oncology: Where is the Behavioral Health Care? [PDF]
Gable KN.
europepmc +1 more source

